American Association for Cancer Research (AACR) Annual Meeting 2015

April 2015, Philadelphia, Pennsylvania
Abstract: Early results from a phase 2 study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer